Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-26483327
- Development stage
- Phase 1
- Lead developer
- Johnson & Johnson Pharmaceutical Research & Development LLC
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-26483327 is an orally bioavailable, small-molecule multitargeted tyrosine kinase inhibitor developed primarily for oncology indications. It inhibits several members of the epidermal growth factor receptor (EGFR) family (including EGFR/ERBB1, HER2/ERBB2, and HER4/ERBB4), Src family kinases (Lyn, Yes, Fyn, Lck and Src), vascular endothelial growth factor receptor 3 (VEGFR3), and RET. By targeting these kinases involved in tumorigenesis and angiogenesis pathways, JNJ-26483327 may inhibit tumor cell proliferation, invasion/migration and metastasis. The drug has demonstrated the ability to cross the blood-brain barrier. Developed by Janssen Pharmaceutica (a subsidiary of Johnson & Johnson), it reached phase I clinical trials for advanced solid tumors but no further development has been reported[1][2][5][7].
- Other names
- 807640-87-5UNII-16720VER1HUNII16720VER1HUNII 16720VER1H
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)SFK (SRC family kinases)ERBB4 (Erb-b2 receptor tyrosine kinase 4)VEGFR3 (Vascular endothelial growth factor receptor 3)EGFR T790M (Epidermal growth factor receptor T790M mutant)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on JNJ-26483327.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-26483327.